Posted by Michael Wonder on 08 Apr 2021
The European Commission grants marketing authorisation for the new subcutaneous administration of Tysabri (natalizumab) to treat relapsing-remitting multiple sclerosis
7 April 2021 - The subcutaneous option provides a shorter administration time and expands access to treatment for patients and physicians beyond the infusion setting.
Biogen today announced that the European Commission has granted marketing authorisation for a subcutaneous injection of Tysabri (natalizumab) to treat relapsing-remitting multiple sclerosis.
